Oncolytics Biotech (Canada)

Recent papers from Oncolytics Biotech (Canada)

1. MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinomaProceedings of the National Academy of Sciences · 2026
2. Ocular Surface Disease as an Immune-related Adverse Event of Immune Checkpoint Inhibitor TherapyCornea · 2026
3. Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national databaseBlood Cancer Journal · 2026
4. Abstract 1221: Imaging mass cytometry of pelareorep treated early breast cancer samples reveals developing tertiary lymphoid structures.Cancer Research · 2026
5. Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinomaInternational Journal of Cancer · 2026
6. Theranostic Potential of a New 64Cu-Labeled NOTA-R954 Peptide Conjugate for Kinin B1R Expressing Prostate CancerPharmaceutics · 2025
7. A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 StudyClinical Cancer Research · 2025
8. Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effectsJournal of Hematology & Oncology · 2025
9. CRISPR screens in neurological research: exploring the functional basis of aging and diseaseBioTechniques · 2025
10. Exceptionally high carbon fixation and nitrogen assimilation rates in microbial mats of an alkaline soda lakeThe ISME Journal · 2025
11. Amphiphilic shuttle peptide delivers base editor ribonucleoprotein to correct the CFTR R553X mutation in well-differentiated airway epithelial cellsNucleic Acids Research · 2024
12. Artificial intelligence: help or hindrance in solving the reproducibility crisis?BioTechniques · 2024
13. Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2024
14. Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.Journal of Clinical Oncology · 2024
15. Abstract PO1-02-01: T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating LymphocytesCancer Research · 2024
16. Granulocyte pro-myeloperoxidase is redundantly processed by proprotein convertase furin and PC7 in HL-60 cellsBiochemistry and Cell Biology · 2024
17. Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell cultureiScience · 2024
18. Assessment of inter-regional dietary differences in anadromous Arctic char (Salvelinus alpinus) in Nunavik, Canada, and links with flesh quality indicatorsArctic Science · 2024
19. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based ImmunotherapiesCancer Immunology Research · 2024
20. Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivoNature Communications · 2023